Results 71 to 80 of about 36,146 (282)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. [PDF]

open access: yes, 2008
PURPOSE: To determine the incidence of and the risk factors for the development of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab (Avastin) injection for the treatment of exudative age-related macular degeneration (AMD). METHODS: A
Brod, Roy   +5 more
core   +2 more sources

Anterior chamber flare and central macular thickness after trabeculectomy versus after phacoemulsification

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To compare the inflammatory response in the eye after trabeculectomy to after phacoemulsification, focusing on anterior chamber flare (AC flare) and central macular thickness (CMT). Methods Data from 436 participants in two randomized controlled trials were analysed.
Yasmeen Ahmed   +5 more
wiley   +1 more source

Deep Learning in Neovascular Age-Related Macular Degeneration

open access: yesMedicina
Background and objectives: Age-related macular degeneration (AMD) is a complex and multifactorial condition that can lead to permanent vision loss once it progresses to the neovascular exudative stage.
Enrico Borrelli   +11 more
doaj   +1 more source

An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration. [PDF]

open access: yes, 2018
Purpose: To evaluate the ability of visual function and structural tests to identify the likely risk of progression from early/intermediate to advanced AMD, using the Age-Related Eye Disease Study (AREDS) simplified scale as a surrogate for risk of ...
Bailey, C.   +3 more
core   +3 more sources

Longitudinal changes in choroidal thickness in high myopia: Correlation with maculopathy progression and visual outcomes

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate longitudinal changes in choroidal thickness (CT) in highly myopic eyes and their correlation with myopic maculopathy progression and visual outcomes. Methods Retrospective cohort study on 1228 eyes from 781 highly myopic patients with a minimum 5‐year follow‐up (mean 11.5 ± 3.1 years).
Matteo Mario Carlà   +8 more
wiley   +1 more source

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis

open access: yesInternational Journal of Retina and Vitreous, 2022
Background Aflibercept is a relatively new anti-VEGF used to treat neovascular age-related macular degeneration (AMD). The purpose of this review is to evaluate the effect of pro re nata (PRN) and fixed regimen (bimonthly) of aflibercept injection for ...
Andi Arus Victor, Yan Martha Putri
doaj   +1 more source

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. [PDF]

open access: yes, 2017
The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability ...
Ambresin, A.   +4 more
core   +1 more source

The prechoroidal cleft in neovascular age‐related macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract The prechoroidal cleft is a lenticular, hypo‐reflective space on optical coherence tomography imaging, located between a band of fibrovascular material underneath the retinal pigment epithelium (RPE) and Bruch's membrane. It occurs in 8%–22% of neovascular age‐related macular degeneration (nAMD) eyes, most often with macular neovascularization
Niels J. Brouwer   +3 more
wiley   +1 more source

Radiation therapy for neovascular age-related macular degeneration

open access: yesClinical Ophthalmology, 2011
Robert Petrarca, Timothy L JacksonDepartment of Ophthalmology, King’s College Hospital NHS Foundation Trust, London, UKAbstract: Antivascular endothelial growth factor (anti-VEGF) therapies represent the standard of care for most patients ...
Robert Petrarca, Timothy L Jackson
doaj  

Home - About - Disclaimer - Privacy